Zacks Research Comments on Pfizer's Q1 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFE - Free Report) - Equities researchers at Zacks Research boosted their Q1 2026 EPS estimates for shares of Pfizer in a note issued to investors on Tuesday, January 21st. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will post earnings of $0.64 per share for the quarter, up from their previous forecast of $0.63. The consensus estimate for Pfizer's current full-year earnings is $2.94 per share. Zacks Research also issued estimates for Pfizer's Q2 2026 earnings at $0.62 EPS.

PFE has been the topic of a number of other research reports. Bank of America reaffirmed a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Evercore ISI raised Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Wolfe Research started coverage on Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price for the company. Finally, Citigroup assumed coverage on shares of Pfizer in a research report on Friday, October 25th. They set a "neutral" rating and a $30.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $32.00.

Pfizer Price Performance

Shares of PFE traded up $0.07 during trading hours on Friday, hitting $26.08. 20,547,254 shares of the company were exchanged, compared to its average volume of 34,075,488. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $147.77 billion, a PE ratio of 35.24, a PEG ratio of 0.64 and a beta of 0.64. The firm has a fifty day simple moving average of $26.08 and a 200-day simple moving average of $27.95. Pfizer has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business's revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.17) EPS.

Institutional Trading of Pfizer

Several institutional investors have recently modified their holdings of PFE. Swiss National Bank grew its position in shares of Pfizer by 0.6% during the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock worth $486,762,000 after buying an additional 100,900 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after purchasing an additional 12,864,343 shares in the last quarter. Empowered Funds LLC boosted its position in shares of Pfizer by 80.9% during the 3rd quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company's stock worth $14,709,000 after purchasing an additional 227,349 shares in the last quarter. Addison Advisors LLC grew its stake in shares of Pfizer by 394.2% in the 3rd quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company's stock valued at $1,512,000 after buying an additional 41,668 shares during the period. Finally, KBC Group NV increased its position in Pfizer by 26.0% in the 3rd quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company's stock valued at $89,872,000 after buying an additional 639,985 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the business's stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company's stock.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.60%. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.